CATHETER PRECISION INC (VTAK) Stock Fundamental Analysis
USA - NYSEARCA:VTAK - US74933X7084 - Common Stock
2.44 USD
-0.12 (-4.76%)
2.4597 USD
+0.02 (+0.81%)
Taking everything into account, VTAK scores 2 out of 10 in our fundamental rating. VTAK was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VTAK have multiple concerns. VTAK shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
VTAK had negative earnings in the past year.
VTAK had a negative operating cash flow in the past year.
In the past 5 years VTAK always reported negative net income.
In the past 5 years VTAK always reported negative operating cash flow.
1.2 Ratios
VTAK's Return On Assets of -94.12% is on the low side compared to the rest of the industry. VTAK is outperformed by 78.31% of its industry peers.
VTAK has a Return On Equity of -354.30%. This is in the lower half of the industry: VTAK underperforms 78.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.12% | ||
| ROE | -354.3% | ||
| ROIC | N/A |
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VTAK's Gross Margin of 92.33% is amongst the best of the industry. VTAK outperforms 98.94% of its industry peers.
The Profit Margin and Operating Margin are not available for VTAK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VTAK has been increased compared to 1 year ago.
Compared to 1 year ago, VTAK has a worse debt to assets ratio.
2.2 Solvency
VTAK has an Altman-Z score of -18.06. This is a bad value and indicates that VTAK is not financially healthy and even has some risk of bankruptcy.
VTAK has a Altman-Z score of -18.06. This is amonst the worse of the industry: VTAK underperforms 88.89% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that VTAK is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, VTAK is in the better half of the industry, outperforming 73.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.06 |
ROIC/WACCN/A
WACC7.41%
2.3 Liquidity
VTAK has a Current Ratio of 0.44. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of VTAK (0.44) is worse than 93.12% of its industry peers.
VTAK has a Quick Ratio of 0.44. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.43, VTAK is not doing good in the industry: 92.59% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.44 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
VTAK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.00%, which is quite impressive.
VTAK shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.61%.
Measured over the past years, VTAK shows a very strong growth in Revenue. The Revenue has been growing by 167.26% on average per year.
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%
3.2 Future
The Earnings Per Share is expected to grow by 40.75% on average over the next years. This is a very strong growth
Based on estimates for the next years, VTAK will show a very strong growth in Revenue. The Revenue will grow by 312.31% on average per year.
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VTAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VTAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VTAK's earnings are expected to grow with 40.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for VTAK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.44
-0.12 (-4.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners1.76%
Inst Owner Change0%
Ins Owners0.83%
Ins Owner Change0%
Market Cap3.64M
Revenue(TTM)600.00K
Net Income(TTM)-24060000
Analysts85.71
Price Target38.76 (1488.52%)
Short Float %6.51%
Short Ratio0.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-59.17%
Min Revenue beat(2)-65.07%
Max Revenue beat(2)-53.27%
Revenue beat(4)0
Avg Revenue beat(4)-65.2%
Min Revenue beat(4)-91.15%
Max Revenue beat(4)-51.31%
Revenue beat(8)0
Avg Revenue beat(8)-68.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1800%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.06 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-73.84
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-6.88
FCFYN/A
OCF(TTM)-6.87
OCFYN/A
SpS0.4
BVpS4.56
TBVpS-11.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.12% | ||
| ROE | -354.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.33% | ||
| FCFM | N/A |
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.08% | ||
| Cap/Sales | 3.83% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.44 | ||
| Quick Ratio | 0.43 | ||
| Altman-Z | -18.06 |
F-Score5
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)3.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.89%
OCF growth 3YN/A
OCF growth 5YN/A
CATHETER PRECISION INC / VTAK FAQ
What is the ChartMill fundamental rating of CATHETER PRECISION INC (VTAK) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VTAK.
What is the valuation status of CATHETER PRECISION INC (VTAK) stock?
ChartMill assigns a valuation rating of 1 / 10 to CATHETER PRECISION INC (VTAK). This can be considered as Overvalued.
Can you provide the profitability details for CATHETER PRECISION INC?
CATHETER PRECISION INC (VTAK) has a profitability rating of 1 / 10.
How financially healthy is CATHETER PRECISION INC?
The financial health rating of CATHETER PRECISION INC (VTAK) is 1 / 10.
What is the earnings growth outlook for CATHETER PRECISION INC?
The Earnings per Share (EPS) of CATHETER PRECISION INC (VTAK) is expected to grow by 96.27% in the next year.